Guidance
← Earnings Calls
01
02
03
04 05 06
Tone
AI
Capex
A1 A2 A3
BMY
FY2026 Q1
Improving
Bristol-Myers Squibb Company earnings call
Buzzberg read
Guidance tracking toward top end of 2026 ranges
Bristol-Myers Squibb's Q1 2026 earnings call highlighted solid performance across its growth portfolio, driven by launches like Qvantig and Breyanzi. Management reaffirmed full-year guidance, signaling confidence by indicating it expects to track towards the upper end of its financial ranges. The call focused heavily on upcoming pivotal readouts (e.g., milvexian, Cobenfi) and the company's strategy on a range of pipeline assets, including its oral cell mods, ADCs, and bispecifics. Total Q1 revenue grew 1% to $11.5B, with the growth portfolio up 9% to $6.2B, led by Breyanzi (+53%), Camzyos (nearly doubled), and Reblozyl (+15%).
Buzzberg read Guidance tracking toward top end of 2026 ranges Bristol-Myers Squibb's Q1 2026 earnings call highlighted solid performance across its growth portfolio, driven by launches like Qvantig and Breyanzi. Management reaffirmed full-year guidance, signaling confidence by indicating it expects to track towards the upper end of its financial ranges. The call focused heavily on upcoming pivotal readouts (e.g., milvexian, Cobenfi) and the company's strategy on a range of pipeline assets, including its oral cell mods, ADCs, and bispecifics. Total Q1 revenue grew 1% to $11.5B, with the growth portfolio up 9% to $6.2B, led by Breyanzi (+53%), Camzyos (nearly doubled), and Reblozyl (+15%). Read full analysisCollapse analysis
Bristol-Myers Squibb's Q1 2026 earnings call highlighted solid performance across its growth portfolio, driven by launches like Qvantig and Breyanzi. Management reaffirmed full-year guidance, signaling confidence by indicating it expects to track towards the upper end of its financial ranges. The call focused heavily on upcoming pivotal readouts (e.g., milvexian, Cobenfi) and the company's strategy on a range of pipeline assets, including its oral cell mods, ADCs, and bispecifics. Total Q1 revenue grew 1% to $11.5B, with the growth portfolio up 9% to $6.2B, led by Breyanzi (+53%), Camzyos (nearly doubled), and Reblozyl (+15%).
- The company reaffirmed full-year 2026 guidance and stated it is tracking towards the upper end of its revenue and EPS ranges.
- Management expressed high confidence in the late-stage pipeline, particularly in upcoming readouts for milvexian (AFib/stroke) and Cobenfi (Alzheimer's psychosis), which are expected by year-end.
- The launch of Qvantig (subcutaneous Opdivo) is progressing well, with over 10% conversion from IV in the US and a target of 30-40% within two years.
GROWTH_PORTFOLIO Revenue$6.2BReported
Revenue$11.489B-8% QoQ
EPS$1.58+25% QoQ
Gross margin70.22%Reported
6 grounded callouts
What matters now
The highest-signal changes from the call.
Pipeline
Late-2026 pivotal readouts to define/de-risk growth
Pipeline
Milvexian hailed as true blockbuster opportunity
Show 3 more callouts
Cell Mods
Cell mod program advancing toward first market entry
Oncology Strategy
Pumitamig strategy: replace PD-1 and expand beyond
Capital Allocation
BD remains size-agnostic with financial flexibility
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| GROWTH_PORTFOLIO Revenue | $6.2B | Reported |
| Revenue | $11.489B | -8% QoQ |
| EPS | $1.58 | +25% QoQ |
| Gross margin | 70.22% | Reported |
| Operating margin | 29.29% | Reported |
| Free cash flow | $0.757B | -53% QoQ |
AI, capex & demand read
Management read
Confident
Management repeatedly emphasized execution, momentum, and tracking toward the upper end of guidance, with conviction in late-stage pipeline catalysts.
Management AI read
AI is discussed as an internal R&D productivity lever, not a product/monetization driver. Management cited broader use of AI tools, lab automation, and partnerships to streamline clinical operations, compress development timelines, and improve trial design.
Investment and capacity
No explicit capex numbers were provided. Management qualitatively noted increased investment in core R&D infrastructure, including AI tools and laboratory automation, enabled partly by the remaining $2 billion Strategic Productivity Initiative savings.
all 1 named companies below
Companiesreturns since call
Partners
Partners
Christian Massachese
BMY's partnership with BNTX on pimmitimig (a PD-1/VEGF bispecific) is progressing well, highlighting a strong collaborative relationship that could drive value for both companies.
Evidence
“the partnership with BioNTech is moving very well because we are progressing the development of this drug with speed.”
External signals
Supply-chain alpha · 3returns since call
Wholesaler inventory dynamics for Eliquis are expected to reverse in Q2, with a build in Q1 and anticipated drawdown, which could smooth out reported revenue trends.
Evidence
“We also saw some wholesaler inventory build in the first quarter. We anticipate this build to reverse in the second quarter.”
A 10% conversion of Opdivo patients to Qvantig (subcutaneous) has already been achieved in the US, with a target of 30-40% conversion over the next two years.
Evidence
“we've now delivered over 10% conversion from IV to Cuvantig in the U.S. in just over a year on the market and we're tracking well against our expectations and we remain confident in our expectation that physicians will convert approximatel…”
BMY is planning a new, more focused study in non-obstructive HCM, indicating a strategic pivot based on learnings from the Odyssey study, potentially enabling a more targeted and successful development path for Camzyos.
Evidence
“So I want to announce that we are planning now to run a new, more focused study in non-obstructive HCM. And then, of course, the detail of it will be highlighted in clinicaltri.gov while we are progressing this work.”
Methodology & coverage
Management-only analysis. All 1 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.